Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Kalvista Pharmaceuticals Inc (KALV)  
$12.06 0.13 (1.07%) as of 4:30 Wed 5/8


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 38,016,000
Market Cap: 458.47(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $7.58 - $16.04
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    : 9.6
Insider 6 Months    : 23.7
Insider 3/6 Months : 33.7
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   KalVista Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. Co. has developed a proprietary portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema. Co.'s primary focus is on developing oral plasma kallikrein inhibitors for HAE. Co. has developed its candidate sebetralstat into clinical development as a potential oral, on-demand therapy for HAE attacks. Co.'s oral product candidate, KVD824 is also being developed for potential prophylactic treatment of HAE.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 29,747 1,251,017 1,251,017 1,251,017
Total Buy Value $437,281 $16,112,140 $16,112,140 $16,112,140
Total People Bought 1 1 1 1
Total Buy Transactions 1 23 23 23
Total Shares Sold 269,594 397,465 480,380 511,543
Total Sell Value $3,953,538 $5,390,948 $6,266,618 $6,542,756
Total People Sold 5 5 6 6
Total Sell Transactions 9 19 30 46
End Date 2024-02-08 2023-11-07 2023-05-09 2022-05-09

   
Records found: 277
  Page 6 of 12  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Feener Edward P. Chief Scientific Officer   •       –      –    2021-06-01 4 AS $26.81 $691,665 D/D (25,800) 22,434 -36%     
   Feener Edward P. Chief Scientific Officer   •       –      –    2021-05-03 4/A AS $24.84 $149,051 D/D (6,000) 48,234     -
   Feener Edward P. Chief Scientific Officer   •       –      –    2021-05-03 4 AS $24.84 $149,051 D/D (6,000) 54,234 -19%     
   Feener Edward P. Chief Scientific Officer   •       –      –    2021-05-03 4 OE $10.21 $61,260 D/D 6,000 60,234     -
   Yea Christopher Chief Development Officer   •       –      –    2021-05-03 4 AS $24.84 $124,197 D/D (5,000) 42,969 -19%     
   Crockett Thomas Andrew CEO   •       •      –    2021-04-29 4 GD $0.00 $0 D/D 4,750 154,670     -
   Maetzel Andreas Senior Vice President, Medical   •       –      –    2021-04-29 4 S $25.04 $1,023,589 D/D (40,886) 0 19%     
   Maetzel Andreas Senior Vice President, Medical   •       –      –    2021-04-29 4 OE $7.91 $437,023 D/D 40,886 40,886     -
   Smith Michael David Senior VP, Development   •       –      –    2021-04-28 4 S $25.76 $257,983 D/D (10,014) 0 20%     
   Smith Michael David Senior VP, Development   •       –      –    2021-04-28 4 OE $8.39 $84,017 D/D 10,014 10,014     -
   Maetzel Andreas Senior Vice President, Medical   •       –      –    2021-04-28 4 S $25.25 $917,985 D/D (36,127) 0 20%     
   Maetzel Andreas Senior Vice President, Medical   •       –      –    2021-04-28 4 OE $7.91 $285,765 D/D 36,127 36,127     -
   Maetzel Andreas Senior Vice President, Medical   •       –      –    2021-04-27 4 S $25.79 $284,163 D/D (11,017) 0 19%     
   Maetzel Andreas Senior Vice President, Medical   •       –      –    2021-04-27 4 OE $7.91 $87,144 D/D 11,017 11,017     -
   Palleiko Benjamin L CFO, CBO & Secretary   •       –      –    2021-02-23 4 AS $31.77 $995,562 D/D (29,642) 65,000 -31%     
   Palleiko Benjamin L CFO, CBO & Secretary   •       –      –    2021-02-23 4 OE $6.74 $199,787 D/D 29,642 94,642     -
   Feener Edward P. Chief Scientific Officer   •       –      –    2021-02-23 4 AS $31.73 $1,041,642 D/D (31,000) 54,234 -31%     
   Yea Christopher Chief Development Officer   •       –      –    2021-02-23 4 AS $31.87 $503,877 D/D (15,000) 47,969 -31%     
   Crockett Thomas Andrew CEO   •       •      –    2021-02-23 4 AS $31.87 $335,538 D/D (10,000) 169,420 -31%     
   Feener Edward P. Chief Scientific Officer   •       –      –    2021-02-07 4 A $0.00 $0 D/D 12,500 85,234     -
   Palleiko Benjamin L CFO, CBO & Secretary   •       –      –    2021-02-07 4 A $0.00 $0 D/D 32,500 65,000     -
   Crockett Thomas Andrew CEO   •       •      –    2021-01-04 4 AS $18.13 $181,904 D/D (10,000) 185,420 39%     
   Feener Edward P. Chief Scientific Officer   •       –      –    2020-11-02 4 AS $17.14 $102,812 D/D (6,000) 72,734 96%     
   Cha Albert Director   –       •      –    2020-10-30 4 B $17.17 $1,994,068 I/I 115,686 1,138,179 2.1 89%     
   Crockett Thomas Andrew CEO   •       •      –    2020-10-29 4 GD $0.00 $0 D/D 6,000 179,420     -
  277 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 6 of 12
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us